Omnia Family Wealth LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 15.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,961 shares of the biopharmaceutical company’s stock after purchasing an additional 4,296 shares during the period. Pfizer makes up 0.5% of Omnia Family Wealth LLC’s holdings, making the stock its 24th biggest position. Omnia Family Wealth LLC’s holdings in Pfizer were worth $1,160,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of PFE. W.G. Shaheen & Associates DBA Whitney & Co acquired a new stake in Pfizer during the first quarter valued at $132,000. Braun Bostich & Associates Inc. acquired a new stake in shares of Pfizer in the first quarter valued at about $139,000. Clearwater Capital Advisors LLC acquired a new stake in shares of Pfizer in the first quarter valued at about $156,000. Goodwin Daniel L acquired a new stake in shares of Pfizer in the second quarter valued at about $171,000. Finally, Bristol John W & Co. Inc. NY acquired a new stake in shares of Pfizer in the first quarter valued at about $186,000. 69.08% of the stock is owned by hedge funds and other institutional investors.
PFE has been the topic of several research analyst reports. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, July 31st. Credit Suisse Group set a $39.00 target price on shares of Pfizer and gave the company a “hold” rating in a research report on Tuesday, July 31st. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, July 31st. Jefferies Financial Group set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research report on Tuesday, July 31st. Finally, BMO Capital Markets lifted their target price on shares of Pfizer from $42.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, August 1st. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $42.67.
PFE opened at $43.51 on Friday. The stock has a market cap of $259.01 billion, a P/E ratio of 14.60, a price-to-earnings-growth ratio of 2.19 and a beta of 0.88. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $45.81. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.03. The firm had revenue of $13.30 billion for the quarter, compared to analyst estimates of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. Pfizer’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.67 earnings per share. Equities analysts predict that Pfizer Inc. will post 3 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be given a dividend of $0.34 per share. The ex-dividend date is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a yield of 3.13%. Pfizer’s payout ratio is presently 51.32%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Recommended Story: Risk Tolerance
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.